A price change from near $21 to $16 is a significant price drop. Granted it’s AH. HGEN might be in a little bit of a pickle in the next month. It APPEARS the primary endpoint was not looking good for trial participants in this blinded trial or more power was needed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.